SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras antibody candidate for menopausal hot flashes, and its Phase 1/2 data presentation at a menopause conference; traders are looking for added evidence on efficacy, durability and safety after encouraging Phase 2 topline results. Bulls see the data as a potential validation of the companys internal pipeline, while skeptics question whether the presentation adds enough beyond known results and warn that expectations and recent volatility may set up a sell-the-news reaction.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

Renewed, unconfirmed takeover chatter around a possible offer from an unidentified West Coast technology company is dominating discussion, with traders speculating about buyers such as Meta while others caution that no bid has been confirmed. Upcoming earnings and concerns about transaction margins are also in focus, but the takeover speculation is driving much of the debate.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak quarterly results, sharply reduced full-year outlook and suspended dividend are driving attention, alongside managements warning of recession-level appliance demand and its attribution of the downturn partly to the Iran war. Traders are debating whether the selloff reflects severe financial and management problems or an overreaction that could create a contrarian buying opportunity; no article was provided that directly supports the catalyst.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas expected Q4 2026 Phase 3 topline results for HLP003, its investigational add-on treatment for major depressive disorder. Traders are split between optimism that the readout could validate the program and concerns about trial uncertainty, potential dilution, and volatility around the binary catalyst.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is drawing attention amid a steep, prolonged selloff, with traders citing weakness across Chinese EV stocks, concerns about demand, profitability and analyst downgrades. Bulls counter that delivery growth, European expansion and AI-chip and robotics initiatives could support the business, while frustrated holders question whether those developments can improve shareholder returns.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs choppy trading is drawing attention amid rotation between small caps and large-cap tech, with traders debating whether small caps relative resilience signals a broader recovery or a temporary bounce. Speculation about a U.S.Iran deal and swings in oil prices have added volatility, but the reported diplomatic progress is disputed and traders remain wary of weak breadth and technical resistance.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Keytruda showed a 42% reduction in recurrence or death risk, but shares sold off as traders judged the outcome against high expectations after a major run-up. The community is split between viewing the data as strong validation of the cancer-vaccine platform and questioning whether the benefit, individualized manufacturing, and commercialization prospects justify the valuation.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillars sharp pullback and upcoming earnings report are driving debate, with traders questioning whether strong backlog and data-center power demand can justify elevated expectations or whether the selloff reflects concerns about slowing AI infrastructure spending. Some see the stock as oversold and are buying the dip, while others expect further weakness if guidance disappoints.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Novartis/Aviditys Phase 3 failure in myotonic dystrophy type 1 has prompted a selloff and focused attention on whether the result also challenges Sareptas SRP-1003 program. Traders debate whether Sareptas different delivery approach and forthcoming DM1 and FSHD readouts can distinguish its pipeline, or whether the rival trial raises the bar for proving functional benefit.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is drawing attention ahead of its earnings report and investor day, with traders also watching hyperscaler results for clues about AI infrastructure demand. The community is divided between expecting strong results and continued growth, and worrying that the broader AI-stock selloff and valuation reset could outweigh solid company fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance

(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third quarter ended September 30, 2026. The company also reaffirmed its full-year 2026 revenue guidance...

GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe

GE HealthCare secures CE Mark certification for MINItrace Magni and expands Copper-64 production capabilities, strengthening its PET imaging and theranostics portfolio.

Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care

(RTTNews) - Friday, Profound Medical Corp. (PROF) and Telix Pharmaceuticals Limited (TLX) announced a co-education agreement to educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided T...

Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Telix Makes $1.65 Billion Bet on ITM to Build a Radiopharma Powerhouse

Telix Pharmaceuticals acquires ITM Isotope for $1.65B to create a radiopharmaceutical leader. Here is what investors need to know.read more...

Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.read more...

Telix Pharma To Acquire ITM In Deal Worth Up To $2.35 Bln

(RTTNews) - Telix Pharmaceuticals Ltd. (TLX,TLX.AX) announced that it signed an agreement to acquire privately held ITM Isotope Technologies Munich SE in a transaction valued at up to US$2.35 billion, strengthening its position in the global radiopharmaceutical and radioisotope m...

FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug

FDA approves Telix Pharmaceuticals' Pixclara, the first radiopharmaceutical brain cancer imaging drug for glioma PET scans.read more...

TLX Stock Clocks 5% Gain This Week Ahead Of FDA Decision On Brain Cancer Imaging Agent 

Equity

The FDA’s target date for deciding on Pixclara is September 11.

Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 86.2% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Telix Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development and commercialization of several clinical-stage oncology assets. The firm operates through the following segments: Therapeutics (Tx), Precision Medicine (Px), and Telix Manufacturing Solutions (TMS). The Tx segment focuses on development of targeted radionuclide therapies for urologic and neurologic oncology, and other solid tumors. The Px segment includes provision of diagnostic imaging solutions to market and expanding into new geographies and indications. The TMS segment comprises of costs to operate the firm's facilities and assets. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East and Africa. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in North Melbourne, Australia.

Telix Pharmaceuticals Ltd. - ADR

Neutral Sentiment

<ul class="summary-bullets"><li>Telix already has two FDA-approved prostate cancer scan drugs: Illuccix, cleared in December 2021, and Gozellix, approved in March 2025.</li><li>Telix has not baked any Pixclara sales into its 2026 forecast, so approval would be extra to current guidance.</li><li>The FDA refused to approve Pixclara in 2025 and sought more evidence.</li></ul><p>NASDAQ-listed shares of Telix Pharmaceuticals (TLX) climbed this week as investors focused on a U.S. Food and Drug Administration (FDA) decision due next Friday on the company’s brain-cancer imaging agent.</p><p>TLX stock was trading around $11.90 on Friday, up roughly 5% from last Friday’s close of $11.29. The biggest lift this week came on Wednesday, when the shares jumped 5.5% after Telix said it had finished enrolling in a late-stage prostate imaging study.</p><h2 class="st-heading-2">Impending Decision</h2><p>The FDA’s target date for deciding on Pixclara is September 11. Pixclara is a PET scan dye meant to help doctors tell whether a glioma — an aggressive brain tumor — is coming back or whether the scan is only showing damage from earlier treatment. That distinction is difficult to make with standard imaging and can affect how patients are treated.</p><p>The product already has Fast Track and Orphan Drug status. Telix has not baked any Pixclara sales into its 2026 forecast, so approval would be in addition to its current guidance of $950 million to $970 million in revenue.</p><h2 class="st-heading-2">A Second Try At The FDA</h2><p>The company first filed for approval of Pixclara in 2024. The FDA accepted the filing and granted it priority review, then rejected it in April 2025 and requested additional supporting evidence. Telix resubmitted in March. The agency accepted the new package on April 10 and set next week’s deadline.</p><p>Telix already has two FDA-approved prostate cancer scan drugs: Illuccix, cleared in December 2021, and Gozellix, approved in March 2025. Those products now drive most sales. A kidney-cancer scan, Zircaix, was also rejected last year and is being prepared for another filing later this year.</p><p>Pixclara would give Telix a third commercial imaging product and a foothold in brain cancer. Approval would also add a product not yet included in the sales outlook, while the core prostate business continues to grow.</p><h2 class="st-heading-2">How Did TLX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around TLX stock remained ‘bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.</p><p><a href="https://stocktwits.com/symbol/TLX">TLX stock</a> has risen 59% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/bidu-stock-up-after-ai-firm-opens-hong-kong-shares-to-mainland-china-investors/cZsDXdgRJD7">BIDU Stock Up After AI Firm Opens Hong Kong Shares To Mainland China Investors</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Telix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The FDA’s target date for deciding on Pixclara is September 11.ecember 2021, and Gozellix, approved in March 2025.Telix has not baked any Pixclara sales into its 2026 forecast, so approval would be extra to current guidance.The FDA r

TLX Stock Clocks 5% Gain This Week Ahead Of FDA Decision On Brain Cancer Imaging Agent

Trust For Professional Managers - ActivePassive International Equity ETF

Telix Pharmaceuticals Limited American Depositary Shares

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$0.06	--	--	N/A
Q3 '26	$0.05	--	--	N/A
Q2 '26	$0.02	--	--	N/A
Q1 '26	$0.00	--	--	N/A
Q4 '25	$0.04	--	--	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

TLX Earnings

Latest Earnings Results: Q3 '26

Historical Earnings